H2AX and cancer: Finally, in recent phase II clinical trials, γ‐H2AX was evaluated as a new pharmacodynamic marker of DNA damage produced by anti‐cancer drugs (Löbrich et al, 2010; Redon et al, 2010; Wu et al, 2013).